CRUK
Personalis MRD Assays to Support UK's TRACERx ctDNA Monitoring Study
The ongoing lung cancer study, which has employed other assays in the past, will now use the Personalis NeXT Personal platform to monitor for recurrence after surgery.
AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).
The researchers envisage deploying a point-of-care assay based on a fluorescent nanophotonics platform.
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.
Cancer Research UK, Partners Announce New Alliance for Early Cancer Detection
CRUK will invest £40 million over the next five years to support the alliance, while US partners will invest $20 million to support research projects and infrastructure.
Nov 30, 2018
Jan 20, 2017